Minimally invasive myotomy for achalasia in the elderly

Arman Kilic1, Matthew J Schuchert, Arjun Pennathur

  • 1Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical Center, 200 Lothrop St., Suite C-800, Pittsburgh, PA, Pennsylvania, 15261, USA.

Surgical Endoscopy
|November 21, 2007
PubMed
Abstract

Insights

Minimally invasive Heller myotomy (MIM) is a safe and effective treatment for achalasia in elderly patients, offering significant symptom improvement. This procedure should be strongly considered for older individuals with this condition.

Area of Science:

  • Gastroenterology
  • Surgical Innovation
  • Geriatric Medicine

Background:

  • Elderly patients with achalasia are increasingly undergoing minimally invasive Heller myotomy (MIM).
  • The risks and outcomes of MIM in this demographic are not fully understood.
  • This study reviews institutional experience with MIM in elderly achalasia patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of minimally invasive Heller myotomy (MIM) in patients aged 70 years and older with achalasia.
  • To define the morbidity and mortality associated with MIM in the elderly population.
  • To compare outcomes of MIM in elderly patients to younger cohorts.

Main Methods:

  • Retrospective analysis of 57 patients (≥70 years) who underwent MIM for achalasia.
  • Procedures were primarily laparoscopic (55) with two videothoracoscopic approaches.
  • Outcomes assessed included postoperative interventions and dysphagia scores (1-5 scale).

Main Results:

  • No perioperative mortality; median hospital stay was 3 days.
  • 19.3% of patients experienced complications, including esophageal perforations and pneumonia.
  • Significant improvement in mean dysphagia score from 3.38 to 1.36 (p < 0.0001), with 96.5% reporting improvement.

Conclusions:

  • Minimally invasive Heller myotomy (MIM) is safe for elderly achalasia patients in experienced centers.
  • MIM provides comparable symptomatic relief in the elderly to younger patients.
  • MIM is a viable therapeutic option for achalasia in older adults.

Related Concept Videos

Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...